← United States · Coverage record
US · SEC FORM 4
Elicio Therapeutics, Inc.
ELTX · Nasdaq · CIK 0001601485 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
0 Form 4 transaction lines observed in the same window
0 sales · 0 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
Insider activity timeline
No Form 4 transaction event is present in the current 180-day window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2023-12-22 · Chudnovsky Yekaterina; GKCC, LLC.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 1,552,675
- Previous report
- 1,666,426
- Avg daily volume
- 377,047
- Days to cover
- 4.1
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2023-12-22 | Chudnovsky Yekaterina; GKCC, LLC | Purchase (P) | Common Stock | 1,213,000 | USD 5.81 | USD 7,047,530 | SEC filing ↗ |
| 2022-05-25 | Venkatesan Jay | Purchase (P) | Common Stock | 11,313 | USD 1.25 | USD 14,141 | SEC filing ↗ |
| 2022-05-24 | Venkatesan Jay | Purchase (P) | Common Stock | 32,200 | USD 1.24 | USD 39,928 | SEC filing ↗ |
| 2022-05-20 | Venkatesan Jay | Purchase (P) | Common Stock | 50,000 | USD 1.23 | USD 61,500 | SEC filing ↗ |
| 2022-05-20 | Nissenson Allen | Purchase (P) | Common Stock | 2,037 | USD 1.18 | USD 2,404 | SEC filing ↗ |
| 2022-05-19 | Nissenson Allen | Purchase (P) | Common Stock | 7,346 | USD 1.16 | USD 8,521 | SEC filing ↗ |
| 2021-12-28 | Venkatesan Jay | Purchase (P) | Common Stock | 210,337 | USD 2.66 | USD 559,496 | SEC filing ↗ |
| 2021-12-27 | Venkatesan Jay | Purchase (P) | Common Stock | 66,907 | USD 2.55 | USD 170,613 | SEC filing ↗ |
| 2021-12-20 | Venkatesan Jay | Purchase (P) | Common Stock | 3,527 | USD 2.54 | USD 8,959 | SEC filing ↗ |
| 2021-12-17 | Venkatesan Jay | Purchase (P) | Common Stock | 13,742 | USD 2.54 | USD 34,905 | SEC filing ↗ |
| 2021-12-16 | Venkatesan Jay | Purchase (P) | Common Stock | 27,883 | USD 2.55 | USD 71,102 | SEC filing ↗ |
| 2021-12-15 | Venkatesan Jay | Purchase (P) | Common Stock | 77,604 | USD 2.41 | USD 187,026 | SEC filing ↗ |
| 2021-12-15 | CURHAN GREGORY S | Purchase (P) | Common Stock | 4,000 | USD 2.37 | USD 9,480 | SEC filing ↗ |
Form 4 evidence
5 transaction lines in the latest 365-day window; 72 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-02-02 | Shah Preetam | Award / grant (A) | Common Stock | 24,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-02 | Haqq Christopher | Award / grant (A) | Common Stock | 25,400 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-02 | DeMuth Peter | Award / grant (A) | Common Stock | 20,800 | USD 0.00 | USD 0 | SEC filing ↗ |
Show recent Form 4 evidence (5 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-02-02 | Shah Preetam | Award / grant (A) | Common Stock | 24,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-02 | Haqq Christopher | Award / grant (A) | Common Stock | 25,400 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-02 | DeMuth Peter | Award / grant (A) | Common Stock | 20,800 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-02 | Connelly Robert | Award / grant (A) | Common Stock | 73,600 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-09 | DeMuth Peter | Option exercise / conversion (M) | Common Stock | 362 | USD 4.41 | USD 1,596 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-19 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | ELTX |
| CIK | 0001601485 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 72 transaction lines from 2021-02-09 to 2026-02-02 13 P purchase lines · 32 S sale lines · 27 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.